| Characteristics | All (119) | without HCC treatment before DAA (105) a | with HCC treatment before DAA (14) b | P a vs b | Recurrence (8) |
| Age (year)* | 68 (18 - 91) | 67 (18 - 91) | 71 (56 - 84) | 0.035 | 68 (65 - 81) |
| Male:Female | 55:64 | 44:61 | 11:3 | 0.01 | 5:3 |
| BMI (Kg/m2) | 22.2 (14.4 - 34.9) | 22.0 (14.4 - 33.2) | 22.5 (18.6 - 34.9) | NS | 24.5 (20.3 - 26.8) |
| DCV/ASV:SOF/RBV:SOF/LDV:OBV/PTV/rit | 43:34:39:3 | 35:31:36:3 | 8:3:3:0 | NS | 3:2:3:0 |
| Duration of the follow-up (months)* DCV/ASV:SOF/RBV:SOF/LD:OBV/PTV/rit (Median) | 32 (24 - 45) 41:31:30:26 | 31 (24 - 45) 41:32:30:26 | 38 (24 - 42) 42:24:26:- | NS | 33 (24-45) 40:28:26:- |
| Previous IFN treatment, Non-responder:Relapse | 15:38 | 15:6 | 0:2 | NS | 0:1 |
| History of HCC treatments (Resection:RFA) | 14 (5:9) | 0 | 14 (5:9) | NS | 8 (4:4) |
| DM | 8 | 5 | 3 | NS | 2 |
| Daily alcohol intake ≥ 40 g/day | 2 | 1 | 1 | NS | 0 |
| HCV RNA (Log IU/ml)* | 5.9 (4.5 - 7.4) | 6.1 (2.3 - 7.4) | 5.6 (4.5 - 7.3) | NS | 6.4 (5.1 - 6.5) |
| White cell count (/μl)* | 5000 (360 - 18,000) | 5000 (360 - 10,600) | 4400 (2600 - 18,000) | NS | 6300 (3600 - 9500) |
| Hemoglobin (g/dl)* | 13.6 (7.3 - 17.2) | 13.6 (7.3 - 17.2) | 13.2 (11.0 - 14.3) | NS | 13.7 (12.4 - 14.3) |
| Platelets (104/μl)* Before | 16.5 (6.9 - 80.9) | 16.6 (6.9 - 34.8) | 12.0 (8.0 - 80.9) | NS | 15.5 (9.9 - 28.4) |
| SVR24 | 17.8 (7.9 - 62.9) | 17.0 (6.3 - 31.2) | 11.8 (7.1 - 66.2) | NS | 15.0 (9.1 - 34.1) |
| Aspartate aminotransferase (IU/L)* | 39 (14 - 361) | 37 (14 - 361) | 46 (27 - 212) | NS | 69 (38 - 116) |
| Alanine aminotransferase (IU/L)* | 42 (12 - 472) | 39 (12 - 472) | 51 (21 - 212) | NS | 67 (23 - 146) |
| Total Bilirubin (mg/dl)* | 0.72 (0.34 - 5.00) | 0.72 (0.34 - 5.00) | 0.67 (0.5 - 1.89) | NS | 0.80 (0.55 - 1.09) |
| Albumin (g/dl)* | 4.2 (2.6 - 5.2) | 4.2 (3.1 - 5.2) | 3.8 (2.6 - 4.6) | NS | 4.0 (3.1 - 4.3) |
| Creatinine (mg/dl)* | 0.71 (0.46 - 8.69) | 0.81 (3.1 - 8.69) | 0.82 (0.56 - 1.15) | NS | 0.91 (0.67 - 1.01) |
| Alpha-fetoprotein (AFP) (ng/ml)* before | 4.0 (1 - 560) | 4.0 (1 - 450) | 9.0 (2 - 560) | 0.01 | 33 (4 - 109) |
| SVR24 | 4.0 (1 - 19) | 3.0 (1.0 - 19) | 17.0 (10 - 47) | 0.002 | 8.0 (6 - 133) |
| Fib-4* at the start of DAA | 2.90 (1.05 - 5.40)) | 2.47 (1.05 - 5.11) | 3.81 (1.52 - 5.40) | NS | 4.35 (2.74 - 5.20) |
| Liver stiffness used the probe M:XL | 109:10 | 96:9 | 13:1 | NS | 7:1 |
| LSM0 (kPa)* | 8.7 (3.0 - 28.8) | 7.5 (3.0 - 28.8) | 15.4 (9.8 - 27.0) | <0.01 | 18.8 (12.1 - 26.0) |
| LSM24 (kPa)* | 6.1 (2.5 - 31.6) | 5.8 (2.5 - 31.6) | 14.8 (5.6 - 26.0) | <0.01 | 21.8 (9.9 - 26.6) |